Shanghai, China, January 8, 2026 –Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women’s health, today announced the appointment of Dr. Ningshu Liu as Chief Scientific Officer (CSO). In this role, Dr. Liu will lead strategy and execution for early-stage drug discovery, build and advance the company’s innovative R&D technology platforms, and help drive pipeline expansion and external partnerships. She will report directly to Dr. Kevin Pan, Founder, Chairman and CEO of Asieris.
Dr. Ningshu Liu brings over 25 years of leadership and R&D experience in targeted oncology and immuno-oncology, spanning roles at both multinational and domestic pharmaceutical companies. Prior to joining Asieris, she served as Co-Chief Scientific Officer at Fosun Pharma’s Global R&D Center，Chairman of FosunPharma S-Infinity, and Senior Vice President of Translational Medicine at Henlius. Previously, Dr. Liu spent over 20 years at Bayer, where she held positions including Sr. Director-Global Strategy Lead, Head of Laboratory Immuno-Oncology, Head of Laboratory Oncogenic Signaling in Bayer Germany, Group leader of Oncology Research in Bayer Research Center USA, Group Manager of Asthma and Inflammation diseases in Bayer Research Center Kyoto, etc.
Dr. Ningshu Liu, Chief Scientific Officer, Asieris Pharmaceuticals
During her tenure at Bayer, Dr. Liu led multiple major R&D programs, advancing several innovative therapies into clinical development. Notably, as program lead, she guided the PI3K inhibitor Copanlisib from early discovery through clinical development to eventual approval by the U.S. Food and Drug Administration (FDA). Furthermore, as the lead and corresponding author for Bayer-affiliated research, Dr. Liu has published more than ten papers in top-tier journals such as Nature Immunology, Cancer Discovery, and Cancer Cell, and has presented numerous times at premier scientific conferences including the Annual Meeting of the American Association for Cancer Research (AACR).
Dr. Kevin Pan commented, “We are delighted to welcome Dr. Ningshu Liu to Asieris. Dr. Liu is an accomplished R&D leader with deep scientific expertise and a strong record of execution. We believe her arrival will strengthen our core R&D capabilities, accelerate the expansion and global development of our proprietary pipeline, and provide powerful scientific momentum for the company’s long-term growth. “
Dr. Ningshu Liu said, “Asieris is a rapidly growing global innovative pharmaceutical company, and I am honored to join. I am deeply impressed by the company’s differentiated innovative pipeline and technology platforms, and I am highly confident in its future. I look forward to leveraging my expertise and experience in this new journey, partnering closely with the team to accelerate pipeline development, and helping bring innovative therapies to patients sooner.”
Dr. Ningshu Liu holds a Bachelor of Science degree in Physiology and Biophysics from Peking University, a Master of Science degree in Biochemistry and Molecular Biology from Tokyo University, and a Ph.D. in Human Medicine from the University of Marburg.
About Asieris
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and women’s health. We strive to improve human health to preserve patient’s dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus.
Through proprietary R&D and strategic collaborations, the company is committed to developing first-in-class drugs and other innovative technologies and products that address significant unmet medical needs, building a robust portfolio spanning from disease diagnosis to treatment within its focused therapeutic areas. Driven by patient needs, we are comprehensively advancing Commercialization 2.0 to improve the accessibility and affordability of innovative products, thereby benefiting more patients in China and globally.